创模生物科技(北京)有限公司

CN / En

NEWS

PDX in vivo efficacy model of InnoModels Biotechnology

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-10-11 15:20
  • Views:

(Summary description)In the vast starry sky of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. is like a bright star, illuminating the journey of oncology and tumor immunology drug development with its unique PDX in vivo efficacy model. Today, let's go into InnoModels Biotechnology to learn more about its industry-leading PDX in vivo efficacy model and explore its unlimited potential in drug discovery and development.

PDX in vivo efficacy model of InnoModels Biotechnology

(Summary description)In the vast starry sky of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. is like a bright star, illuminating the journey of oncology and tumor immunology drug development with its unique PDX in vivo efficacy model. Today, let's go into InnoModels Biotechnology to learn more about its industry-leading PDX in vivo efficacy model and explore its unlimited potential in drug discovery and development.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-10-11 15:20
  • Views:
Information

In the vast starry sky of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. is like a bright star, illuminating the journey of oncology and tumor immunology drug development with its unique PDX in vivo efficacy model. Today, let's go into InnoModels Biotechnology to learn more about its industry-leading PDX in vivo efficacy model and explore its unlimited potential in drug discovery and development.
InnoModels Biotechnology: Leading in Technology, Innovating for the Future
Founded by scientists from Novo Nordisk China R&D Center, Sino-American Champion and the Institute of Immunology of Shanghai Jiao Tong University, InnoModels Biotechnology (Beijing) Co., Ltd. has been carrying the mission of promoting the research and development of oncology and oncology immunotherapeutics since the day of its birth. The company focuses on oncology and tumor immunopharmacodynamics CRO services, translational medicine research services, and individualized healthcare, and is committed to providing new generation of experimental animal models close to the clinic for new drug discovery and development companies, translational medicine researchers, and tumor patients.
PDX in vivo pharmacodynamic model: a perfect blend of stability and efficacy
In the broad arena of oncology research, the PDX (Patient-Derived Xenograft) model has attracted much attention for its ability to highly mimic the biological characteristics of patients' tumors. Based on this, with profound scientific research strength and technological innovation, InnoModels Biotechnology has successfully created the PDX in vivo drug efficacy model, which provides a powerful tool for the development and evaluation of oncology drugs.
The model ensures the heterogeneity of tumor tissues and the complete retention of genomic information through primary cell inoculation technology, which makes the drug efficacy response and clinical consistency as high as over 90%. This breakthrough not only dramatically improves the success rate of modeling and the stability of experiments, but also enables the model to achieve uniform growth at an early stage, which lays a solid foundation for the smooth conduct of efficacy experiments.

 


Double guarantee of stability and efficacy
The uniqueness of InnoModels Bio's PDX in vivo potency model lies in its ability to homogenize samples from the same batch. The cell suspension modeling method ensures a high degree of consistency in growth rate and biological characteristics between samples in the same batch, thus guaranteeing the long-term stability of the model. This stability not only makes the experimental results more reliable, but also significantly reduces the experimental cost and improves the experimental efficiency.
In addition, the model has excellent scalability and can be combined with the PBMC (peripheral blood mononuclear cell) immune system humanization model to constitute a tumor-immune system dual humanization model. This innovative design provides a more comprehensive and realistic research platform for the development of new tumor immune drugs, and greatly promotes the research progress of tumor immunotherapy.
Practical application: rapid screening of DS-8201 drug resistance models
During the development of DS-8201 (fam-trastuzumab deruxtecan-nxki), a HER2-targeted ADC drug, InnoModels Biotechnology has successfully screened several HER2-positive DS-8201 resistance models with its efficient PDX model library. The discovery of these models not only provides valuable resources for the further development of HER2 ADC therapies, but also brings new hope for the treatment of DS-8201-resistant patients.
Conclusion
With its excellent stability, high efficiency and wide application prospects, the PDX in vivo drug efficacy model of InnoModels Biotechnology is gradually becoming an important force in the field of oncology and tumor immunology new drug development. In the days to come, we have reason to believe that InnoModels Biotechnology will continue to uphold the concept of technology leadership and innovation for the future, and contribute more wisdom and strength to the field of tumor therapy.

Keyword:

With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
In the vast field of drug discovery and life science research, InnoModels Biotechnology (Beijing) Co., Ltd. is gradually becoming a leader in the industry with its IC50 platform. The platform not only integrates advanced detection technologies, abundant cell resources and strict quality control system, but also provides researchers with efficient and reliable experimental solutions through continuous innovation and optimization.
In the field of life sciences, every leap in technology leads to deeper research and medical advances. InnoModels Biotechnology (Beijing) Co., Ltd, with its innovative 3D organoid platform, is providing scientists with an unprecedented research tool, which greatly promotes drug research and development and the exploration of disease mechanisms
In the vast starry sky of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. is like a bright star, illuminating the journey of oncology and tumor immunology drug development with its unique PDX in vivo efficacy model. Today, let's go into InnoModels Biotechnology to learn more about its industry-leading PDX in vivo efficacy model and explore its unlimited potential in drug discovery and development.
Previous page
1
2
42
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司